April 17 (Reuters) - Eli Lilly's weight-loss drug succeeded in two late-stage trials testing it in patients with obstructive sleep apnea, the company said on Wednesday. (Reporting by Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
737.2 USD | +0.50% | +0.80% | +26.47% |
Apr. 29 | Equity Markets Rise With Key Earnings, Fed Decision in Focus | MT |
Apr. 29 | US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B | |
-10.94% | 144B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients